Amyotrophic Lateral Sclerosis
Conditions
Brief summary
In this proposed study, the investigators will evaluate the safety and efficacy of lipoic acid in treatment of Amyotrophic lateral sclerosis (ALS). The study will recruit 150 AD patients, and then these patients will be randomized to lipoic acid group or control group (75 patients per arm) for 6 courses for about 5 months. Clinical assessment will be done at screen/baseline, 3th course and 6th course. The specific aims are to compare lipoic acid versus control on: motor function and disease progression. During the study period, clinical effect index will be recorded, including bulbar function, motor function, respiratory function, and safety index including blood and urine routine, liver and kidney function, coagulation function.
Detailed description
In this proposed study, the investigators will evaluate the safety and efficacy of Lipoic acid in treatment of ALS. The study will recruit 150 ALS patients, then these patients will be randomized to lipoic acid group or control group (75 patients per arm) for 6 courses for about 5 months. Clinical efficacy and safety assessment will be done at screen/baseline, 3th course and 6th course. The specific aims are to compare lipoic acid versus placebo on: (1) Lipoic acid could improve the motor function, delay the disease progression and extend survival time in patients with ALS, measured by the ALSFRS-R Scale, ROADS Scale, upper motor neuron Scale, Muscle strength Scale and Electromyography; (2) Lung function will be collected to prove the hypothesis lipoic acid may help respiratory function. (3) Safety index including blood and urine routine, liver and kidney function, coagulation index will be recorded.
Interventions
DRUGlipoic acid group
The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day. At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day.
DRUGcontrol group
The patients will take domestic riluzole tablets 50mg orally, twice a day.
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
outcomes assessors who do all the scales are concealed of group allocation.
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age range from 20 to 75 (including 20 and 75 years old), regardless of ethnic group or gender; 2. The subjects should meet the diagnostic criteria for ALS by El Escorial revised criteria: Definite ALS, Probable ALS and Probable, laboratory-supported ALS. 3. ALS Functional Rating Scale-Revised (ALSFRS-R 12 items) each item score ≥2 points; 4. The onset (the symptoms of limbs weakness, muscle atrophy or bulbar involvement ) of the disease is less than 2 years 5. Baseline breath function: Forced Vital Capacity≥70% . 6. Disease Progression Rate FS=(48- ALSFRS-R at time of diagnosis)/duration from onset to diagnosis (month), progression rate FS≤1;
Exclusion criteria
1. Combined with one of cerebrovascular disease, spinal cord disease, spinal muscular atrophy, juvenile myoatrophy of distal upper extremity, multifocal motor neuropathy, Kennedy disease, epilepsy, etc; 2. Severe renal insufficiency: creatinine clearance rate \<30 mL/min (Cockcroft-Gault formula, urea nitrogen and (or) blood creatinine\> 1.5 times the upper limit of normal, or other known severe renal insufficiency diseases; 3. Severe liver damage: ALT, AST\> 3 times the upper limit of normal, or other known liver diseases such as acute and chronic hepatitis, cirrhosis, etc.; 4. Obvious tachycardia or bradycardia; patients with acute myocardial infarction or interventional therapy in the past 6 months (patients with grade III-IV according to NYHA classification); 5. Combined with malignant tumor, blood, digestion or other serious diseases; 6. Female patients during pregnancy and lactation; 7. Participated in other clinical trials within 30 days before randomization, or are participating in other clinical trials;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change of Amyotrophic lateral sclerosis Function Rate Scale-Revised (ALSFRS-R) | change from baseline to 11th week& 21th week | The Amyotrophic lateral sclerosis Function Rate Scale-Revised (ALSFRS-R) will be performed to test the motor function of patients at the enrollment, 3th course and 6th course . The score ranges from 0 to 48#and higher scores represent a better motor function. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change of Rasch Overall ALS Disability Scale (ROADS) | change from baseline to 11th week& 21th week | Rasch Overall ALS Disability Scale (ROADS) will be performed to test the motor function of patients at the enrollment, 3th course and 6th course . The score ranges from 0 to 56#and higher scores represent a better motor function. |
| change of Upper motor neuron scale (UMNS) | change from baseline to 11th week& 21th week | Upper motor neuron scale(UMNS) will be performed to test the motor function of patients at the enrollment, 3th course and 6th course . The score ranges from 0 to 33. |
| change of Muscle strength scale | change from baseline to 11th week& 21th week | Muscle strength scale will be performed to test the muscle strength of patients at the enrollment, 3th course and 6th course. Higher scores represent a better muscle strength. |
| change of Pulmonary Forced Vital Capacity (PFVC) | change from baseline to 11th week& 21th week | Pulmonary Forced Vital Capacity (PFVC) will be performed to test the breath function of patients at the enrollment, 3th course and 6th course. Higher scores represent a better pulmonary function. |
| change of Motor Neuron Disease Electromyography | change from baseline EMG to 21th week | Motor Neuron Disease Electromyography will be performed to test the electrical activity of muscles of patients at the enrollment, 3th course and 6th course . |
Other
| Measure | Time frame | Description |
|---|---|---|
| Endpoint events occur rate | at 21th week | Endpoint events occur rate, including death, tracheotomy, invasive ventilator assisted ventilation or continuous noninvasive ventilator assisted ventilation (use time ≥22 hours per day, duration ≥10 days); |
| percentage of adverse drug reaction | At the baseline, 11th week and 21th week | Check the percentage of adverse drug reactions in blood routine, blood biochemistry, and urine routine |
Countries
China
Contacts
Primary Contactzhiying wu, Ph.D
Outcome results
None listed